Stage 5: Commissioning (Week 8)
A MedTech Innovation Briefing (MIB) is a document produced by the National Institute for Health and Care Excellence (NICE). The purpose of a MIB is to create a document that can be used by commissioners, patients, patient groups and the NHS to find out about the current technologies and treatment options for a condition. A MIB will therefore describe a technology, how it is used and the potential role that it could have in the treatment pathway 1 . A MIB will also review all of the published evidence about a technology that is considered relevant, and assess its likely costs. NICE first developed the briefings in 2013 to help boost and speed-up the uptake of innovative and promising technologies that have the potential to improve patient health and increase NHS productivity (Figure 1) The number of MIBs produced each year has steadily increased between 2014 and 2016 from 17 to 42 (Figure 2 and 3) . Across all years, devices with a Class IIa or IIb CE mark remained the most common technologies selected for evaluation (Figure 4) , as did technologies with a purchasing price between £1,000 and £10,000. Our analysis also revealed that across this timeframe, the majority of MIBs (78%) did not contain comments from patient organisations or carers. However, all briefings contained contributions from three or more specialists.
Results
Our research has highlighted that whilst the number of MIBs produced each year is increasing, there remains limited patient group involvement in the development process. Due to the absence of a NICE recommendation and NHS funding mandate, MIBs are typically perceived as low profile assessments. This may contribute to the observed limited patient engagement. With the development of MedTechScan 4 to identify technologies suitable for NICE evaluation, the quantity and diversity of MIBs is likely to increase. Implementing the Government's Accelerated Access Review 5 recommendations to provide funding for medical technologies approved by NICE is expected to raise the status of MIBs. Stage 2: Eligibility (Week 2-3)
The Medical Technologies Evaluation Programme (MTEP) team assess the topics against the eligibility criteria. Topics which are not eligible are removed.
Step 3: Selection framework (Week 3-5)
The MTEP team assess topics against the selection framework. Topics which meet the selection framework are selected for MIB production.
Step 4: Oversight and prioritisation (Week 6-7)
The MTEP team presents the topics to the Medical Technologies Topic Oversight Group (MTTOG) for approval. The advice from MTTOG is used to produce a prioritised commissioning schedule. 
